SecurityAYTU / Aytu BioScience, Inc. (054754106)
IndustryPharmaceutical Preparations
Institutional Owners1
Institutional Shares1 - 0.00%
Common Shares Outstanding35,888,069 shares (as of 2018-03-31)
Related AYTUZ / Aytu BioScience, Inc. Warrant

Institutional Stock Ownership and Shareholders()

AYTU / Aytu BioScience, Inc. Institutional Ownership

Aytu BioScience, Inc. (NASDAQ:AYTU) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1 shares. Largest shareholders include Barclays Plc.
Aytu BioScience, Inc. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/aytu"><img src="https://images.fintel.io/us-aytu-so.png" alt="AYTU / Aytu BioScience, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-04-10 13F-HR Hartford Financial Management Inc. 7,000 0 -100.00 15 0 -100.00
2018-07-20 13F-HR MCF Advisors LLC 357,142 0 -100.00 227 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 1 1 0.00 0 0

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Aytu BioScience Announces Enrollment of First Twenty Patients in the Natesto(R) Spermatogenesis Study

2018-07-17 accesswire
University of Miami Study is First to Assess Natesto's Impact on Sperm Production and Gonadotropin Levels (48-1)

Trump Nabs Win Over Pfizer But Other Companies Continue With Price Increases

2018-07-13 biospace
President Donald Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year following a call between Trump and Pfizer Chief Executive Officer Ian Read. Other companies though have not followed suit and have gone through with price increases for their drugs. (54-0)

Pharmaceutical companies ignore Donald Trump and raise drug prices

2018-07-12 theage.com.au
US President Donald Trump bragged may have bragged about convincing Pfizer to hold off on price increases, but the pharmaceutical giant isn't the only drug company looking to charge more for its products. (51-1)

Pharmaceutical companies ignore Donald Trump and raise drug prices

2018-07-12 smh.com.au
US President Donald Trump bragged may have bragged about convincing Pfizer to hold off on price increases, but the pharmaceutical giant isn't the only drug company looking to charge more for its products. (51-1)

Many Drugmakers Ignore Trump—and Raise Prices Anyway - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (54-0)

CUSIP: 054754106